Roche reached an agreement to acquire LumiraDx's point-of-care testing technology, the companies announced on Dec. 29. Roche will pay $295 million upfront and an additional amount up to $55 million to ...

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Lumira Ventures, a life sciences investment firm dedicated to supporting healthcare innovation and patient impact, is proud to announce several significant ...

Just one year after launch, the Fund was oversubscribed with participation from leading Canadian cancer charities, impact investors, institutional investors and family offices. TORONTO, May 5, 2026 ...

During the past 18 months Lumira Ventures completed 8 exit transactions and portfolio companies received 2 FDA new product approvals and raised over US$800M via IPOs and public and private financings ...

Toronto-based Lumira Ventures has raised $276 million CAD ($220 million USD) for Fund IV, which Lumira claims is “the largest institutional life sciences venture capital fund ever raised in Canada.” ...

Lumira Ventures announced the first closing of Lumira Ventures V, LP, its latest healthcare-focused venture fund, targeting a final size of $200 million. The fund will focus on building biotechnology ...

Lumira Ventures has raised the largest Canadian life sciences venture capital fund in two decades, drawing US$220-million from investors. But Lumira managing general partner Peter van der Velden ...

The Lumira delivers a wavelength range of 440 to 490 nm and up to 3,000 mW/cm² irradiance for efficient curing, with a collimated beam that supports a reliable depth of cure in deep restorations.